Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, Peveling Genannt C.; Gräven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. and Heinemann, V.
(2017):
Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): german AIO KRK0110 (ML22011) - study.
In: Oncology Research and Treatment, Vol. 40: p. 123
| Item Type: | Journal article |
|---|---|
| Faculties: | Medicine |
| Subjects: | 600 Technology > 610 Medicine and health |
| ISSN: | 2296-5270 |
| Language: | English |
| Item ID: | 51828 |
| Date Deposited: | 14. Jun 2018, 09:47 |
| Last Modified: | 14. Jun 2018, 09:47 |
Actions (login required)
- View Item
